The FDA's decision to maintain the clinical hold on Entrada Therapeutics' IND application directly impacts the company's ability to proceed with clinical trials, which is a critical step in drug development. This regulatory setback is likely to negatively affect investor sentiment and the stock price in the short term, as it delays potential product development and revenue generation.